Compare AbCellera Biologics Inc (ABCL) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Vanguard Real Estate Index Fund ETF trades at $97.24. Which is the better fit depends on your goals.
| ABCL | VNQ | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $98.66 |
52-Week Low | $2.78 | $87.00 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VNQ (Vanguard Real Estate ETF) trades at $97.24, down 0.8% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF's recent performance reflects renewed investor interest in REITs amid shifting rate expectations, with June 2026 marking the sector's best monthly performance in years according to market data. Dividend payments remain a key attraction, with the next distribution scheduled for June 2026.
The outlook for VNQ appears cautiously optimistic as REIT fundamentals show resilience despite elevated interest rates. Investment opportunity lies in potential rate stabilization and sector rotation, while risks include persistent inflation pressure and Treasury yield volatility. Analyst sentiment is mixed, with some highlighting discounted valuations while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
